Simcere Pharmaceutical Group Limited

As of December 31, 2025, SIMCERE PHARMACEUTICAL GROUP LTD carries a market capitalization of 5.14B, placing it among publicly traded companies globally. Its enterprise value stands at 4.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SIMCERE PHARMACEUTICAL GROUP LTD's next confirmed earnings release is scheduled for March 25, 2027.

As of December 31, 2025, SIMCERE PHARMACEUTICAL GROUP LTD has 2.60B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, SIMCERE PHARMACEUTICAL GROUP LTD maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 3, 2026, SIMCERE PHARMACEUTICAL GROUP LTD's stock has gained approximately 95.03% over the past 52 weeks.

As of December 31, 2025, SIMCERE PHARMACEUTICAL GROUP LTD holds 511.63M in cash and equivalents against 169.74M in total debt, resulting in a net debt position of -350.68M. Total book value stands at 1.35B, with working capital of 578.43M providing operational flexibility.